Center for Diagnostic Nanosystems, Marshall University, Huntington, WV, United States.
Department of Public Health, Marshall University, Huntington, WV, United States.
Exp Clin Endocrinol Diabetes. 2020 Aug;128(8):512-519. doi: 10.1055/a-0815-4908. Epub 2019 Jan 7.
Empagliflozin, a known inhibitor of sodium-glucose cotransporter type 2 (SGLT2) decreases glucose reabsorption by the renal tubules and promotes glucose excretion into the urine. While the effectiveness of Empagliflozin in the management of hyperglycemia along with associated cardiovascular and all-cause mortality has been demonstrated previously, the therapeutic benefits associated with the long-term use of this drug in obese animals have yet to be investigated.
Male 5-week-old lean and obese Zucker rats were randomly assigned to one of the 4 groups- lean control, lean treated, obese control, obese treated and treated with either Empagliflozin (10 mg/kg BW / day) or placebo for 25 weeks to investigate the therapeutic effect of Empagliflozin.
Empagliflozin treatment in the obese animals was associated with decreased body weight, attenuated the loss of F-actin from the renal tubules and improved renal structure and function. These changes in renal function were associated with significant improvements in the glucose tolerance, and decreased non-fasting circulatory levels of glucose, amylase, and other inflammatory markers including NGAL, cystatin C, and clusterin.
Long-term use of Empagliflozin in diabetic obese Zucker rats is associated with improvements in glucose tolerance and decreased loss of renal structure and function.
恩格列净是一种已知的钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂，可减少肾脏对葡萄糖的重吸收，并促进葡萄糖排入尿液。虽然此前已经证明恩格列净在治疗高血糖以及相关的心血管和全因死亡率方面的有效性，但尚未研究这种药物在肥胖动物中的长期使用所带来的治疗益处。
5 周龄雄性瘦型和肥胖型 Zucker 大鼠被随机分为 4 组-瘦型对照组、瘦型治疗组、肥胖型对照组、肥胖型治疗组，并接受恩格列净（10mg/kg BW/天）或安慰剂治疗 25 周，以研究恩格列净的治疗效果。
在肥胖动物中，恩格列净治疗与体重减轻、肾脏管腔中 F-肌动蛋白丢失减少以及肾功能和结构改善有关。这些肾功能的变化与葡萄糖耐量的显著改善以及非空腹循环中葡萄糖、淀粉酶和其他炎症标志物（包括 NGAL、胱抑素 C 和簇蛋白）水平的降低有关。
长期使用恩格列净治疗肥胖型糖尿病 Zucker 大鼠可改善葡萄糖耐量并减少肾脏结构和功能的丧失。
